Anna Aleksandrovna Kravtsova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna Aleksandrovna Kravtsova has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Elena Parovichnikova
National Medical Research Center of Hematology
2 shared publications A. A. Korobkova
National Medical Research Center for Hematology, Ministry of Health of Russia
1 shared publication- Aminat U. Magomedova
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
1 shared publication - D. S. Belkina
National Medical Research Center for Hematology, Ministry of Health of Russia
1 shared publication - Ekaterina A. Fastova
National Medical Research Center for Hematology
1 shared publication - Ekaterina Sergeevna Nesterova
National Medical Research Center for Hematology, Ministry of Health of Russia
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 453-463
Post-Transplantation Cyclophosphamide: From Pharmacological Principles to Clinical Practice
Despite a considerable increase in the number of bone marrow donor registries, only 16–75 % of patients potentially have a fully matched unrelated donor, and an HLA-matched donor is not easy to find even among family members. Historically, the use of partially HLA-matched related (haploidentical) donors have been limited due to the high incidence of graft-versus-host disease (GvHD), high non-relapse mortality, and low overall survival rates. Efforts to improve the results of haploidentical transplantation were aimed at the depletion of graft T-cells. Although the ex vivo T-cell depletion virtually eliminates the possibility of GvHD, such allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with a high relapse risk and high mortality from infectious complications. To selectively deplete T-cells, a GvHD prevention method was elaborated, which uses high doses of cyclophosphamide (post-transplantation cyclophosphamide, PTCy). The administration of PTCy on Day +3 and Day +4 after transplantation results in elimination of alloreactive T-cells, which considerably reduces the incidence of acute and chronic GvHD and improves antitumor control. This method allowed to overcome the HLA barrier and to achieve survival rates after haplo-HSCT similar to those after HLA-matched transplantation. This review also addresses the pharmacological basis of biological effects of PTCy and analyzes the key clinical findings on the use of PTCy in allo-HSCT.
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 453-463
Open AccessPost-Transplantation Cyclophosphamide: From Pharmacological Principles to Clinical Practice
Despite a considerable increase in the number of bone marrow donor registries, only 16–75 % of patients potentially have a fully matched unrelated donor, and an HLA-matched donor is not easy to find even among family members. Historically, the use of partially HLA-matched related (haploidentical) donors have been limited due to the high incidence of graft-versus-host disease (GvHD), high non-relapse mortality, and low overall survival rates. Efforts to improve the results of haploidentical transplantation were aimed at the depletion of graft T-cells. Although the ex vivo T-cell depletion virtually eliminates the possibility of GvHD, such allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with a high relapse risk and high mortality from infectious complications. To selectively deplete T-cells, a GvHD prevention method was elaborated, which uses high doses of cyclophosphamide (post-transplantation cyclophosphamide, PTCy). The administration of PTCy on Day +3 and Day +4 after transplantation results in elimination of alloreactive T-cells, which considerably reduces the incidence of acute and chronic GvHD and improves antitumor control. This method allowed to overcome the HLA barrier and to achieve survival rates after haplo-HSCT similar to those after HLA-matched transplantation. This review also addresses the pharmacological basis of biological effects of PTCy and analyzes the key clinical findings on the use of PTCy in allo-HSCT.
- Open Access
- 30 September 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (3) , 146-158
Model development for an additional professional retraining program in hematology in order to improve the quality of medical care
Aim of the study – to develop a curriculum for a Continuing Professional Education program – specifically, a Professional Retraining (PR) program in the specialty of “Hematology” – that meets modern clinical challenges, professional and educational standards, and the expectations of the medical community. This article presents and describes the methodological approaches to developing the curriculum for the PR program in “Hematology”, which is focused on advancing and enhancing modern technological directions for the diagnosis and treatment of blood system disorders. It also addresses clinical tasks fundamentally based on the labor functions outlined in the professional standard. The program structure is based on a modular principle with a clearly traceable practice-oriented focus. To assess the relevance and applicability of the PR program, a survey was conducted among chief freelance hematology specialists from the constituent entities of the Russian Federation, practicing hematologists, and medical university faculty. The survey results helped identify the most significant thematic blocks, reveal differences in educational priorities, and formulate recommendations for adapting the professional retraining program according to the varying conditions of real clinical practice in medical organizations specializing in hematology.
- 30 September 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (3) , 146-158
Open AccessModel development for an additional professional retraining program in hematology in order to improve the quality of medical care
Aim of the study – to develop a curriculum for a Continuing Professional Education program – specifically, a Professional Retraining (PR) program in the specialty of “Hematology” – that meets modern clinical challenges, professional and educational standards, and the expectations of the medical community. This article presents and describes the methodological approaches to developing the curriculum for the PR program in “Hematology”, which is focused on advancing and enhancing modern technological directions for the diagnosis and treatment of blood system disorders. It also addresses clinical tasks fundamentally based on the labor functions outlined in the professional standard. The program structure is based on a modular principle with a clearly traceable practice-oriented focus. To assess the relevance and applicability of the PR program, a survey was conducted among chief freelance hematology specialists from the constituent entities of the Russian Federation, practicing hematologists, and medical university faculty. The survey results helped identify the most significant thematic blocks, reveal differences in educational priorities, and formulate recommendations for adapting the professional retraining program according to the varying conditions of real clinical practice in medical organizations specializing in hematology.
- 26 August 2026
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 26 (4)
Lymphoproliferative diseases during pregnancy. Long-term outcomes for mother and child
Lymphoproliferative diseases are the third most common type of malignant neoplasms detected in pregnant patients. The high effectiveness of the therapy of such patients makes it relevant to study the long-term results of their treatment, as well as the health status of their children. Objective. To present the features of the course of pregnancy and its outcomes in patients with an identified lymphoproliferative disease during pregnancy, to evaluate the long-term effects of the treatment, as well as to analyze the physical development of children born to mothers with lymphoma, at birth and in the catamnesis. Materials and methods. From 2009 to 2025, 44 patients with a diagnosis of lymphoproliferative disease during pregnancy were treated at the Federal State Budgetary Institution “NMRC of Hematology” of the Ministry of Health of the Russian Federation. 28 (64%) pregnant women were diagnosed with non-Hodgkin’s lymphoma, 16 (36%) with Hodgkin’s lymphoma. Among 44 patients, 36 (82%) underwent chemotherapy during pregnancy, in 8 (18%), treatment was postponed until delivery. The median age of the patients at the time of the disease detection was 30 (range 20-39) years. In this retrospective single-center cohort study, we analyzed the development of 46 children born to 44 patients with detected lymphoma during gestation. Results. 43 (98%) of the 44 patients have been alive and are in remission of the disease with a median observation of 56 (range 2-186) months. 30 (68%) patients achieved complete remission after the first line of therapy. The remaining 14 (32%) patients required a second and subsequent line of treatment due to failure of the initial therapy. 6 (14%) cases of disease progression were registered during chemotherapy. Early relapses (1 year) — in 1 (2%) case. One patient died in the late postpartum period from septic complications after high-dose chemotherapy due to the progression of the disease. The median gestational age of newborns was 36 (range 26-40) weeks, 27 of 46 children (61%) were born prematurely. 22 newborns (49%) required follow-up in the intensive care unit. Congenital malformations of the cardiovascular system were detected in 2 babies (4%): 1 case (2%) of an open ductus arteriosus and 1 case (2%) of an interventricular septal defect. However, none of the identified pathological conditions required surgical intervention. At the time of the study, the median age of the children was 5.0 (range 0.3—15.3) years. The following LEN organs diseases were diagnosed later for 11 months among 46 children : adenoid hypertrophy — n=4 (9%), tonsillitis — n= 1 (2%), laryngitis — n=3 (7%), otitis media — n=3 (7%). One child (2%), whose mother did not receive chemotherapy during pregnancy, was diagnosed with cerebral palsy in the first year of life. Conclusion. Despite the diagnostic and therapeutic difficulties in verifying lymphoproliferative diseases during pregnancy, as well as the high frequency of premature birth, long-term catamnesis observations demonstrate favorable outcomes. The patients have long-term remissions, and the condition of their children is satisfactory in most cases.
- 26 August 2026
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 26 (4)
Lymphoproliferative diseases during pregnancy. Long-term outcomes for mother and child
Lymphoproliferative diseases are the third most common type of malignant neoplasms detected in pregnant patients. The high effectiveness of the therapy of such patients makes it relevant to study the long-term results of their treatment, as well as the health status of their children. Objective. To present the features of the course of pregnancy and its outcomes in patients with an identified lymphoproliferative disease during pregnancy, to evaluate the long-term effects of the treatment, as well as to analyze the physical development of children born to mothers with lymphoma, at birth and in the catamnesis. Materials and methods. From 2009 to 2025, 44 patients with a diagnosis of lymphoproliferative disease during pregnancy were treated at the Federal State Budgetary Institution “NMRC of Hematology” of the Ministry of Health of the Russian Federation. 28 (64%) pregnant women were diagnosed with non-Hodgkin’s lymphoma, 16 (36%) with Hodgkin’s lymphoma. Among 44 patients, 36 (82%) underwent chemotherapy during pregnancy, in 8 (18%), treatment was postponed until delivery. The median age of the patients at the time of the disease detection was 30 (range 20-39) years. In this retrospective single-center cohort study, we analyzed the development of 46 children born to 44 patients with detected lymphoma during gestation. Results. 43 (98%) of the 44 patients have been alive and are in remission of the disease with a median observation of 56 (range 2-186) months. 30 (68%) patients achieved complete remission after the first line of therapy. The remaining 14 (32%) patients required a second and subsequent line of treatment due to failure of the initial therapy. 6 (14%) cases of disease progression were registered during chemotherapy. Early relapses (1 year) — in 1 (2%) case. One patient died in the late postpartum period from septic complications after high-dose chemotherapy due to the progression of the disease. The median gestational age of newborns was 36 (range 26-40) weeks, 27 of 46 children (61%) were born prematurely. 22 newborns (49%) required follow-up in the intensive care unit. Congenital malformations of the cardiovascular system were detected in 2 babies (4%): 1 case (2%) of an open ductus arteriosus and 1 case (2%) of an interventricular septal defect. However, none of the identified pathological conditions required surgical intervention. At the time of the study, the median age of the children was 5.0 (range 0.3—15.3) years. The following LEN organs diseases were diagnosed later for 11 months among 46 children : adenoid hypertrophy — n=4 (9%), tonsillitis — n= 1 (2%), laryngitis — n=3 (7%), otitis media — n=3 (7%). One child (2%), whose mother did not receive chemotherapy during pregnancy, was diagnosed with cerebral palsy in the first year of life. Conclusion. Despite the diagnostic and therapeutic difficulties in verifying lymphoproliferative diseases during pregnancy, as well as the high frequency of premature birth, long-term catamnesis observations demonstrate favorable outcomes. The patients have long-term remissions, and the condition of their children is satisfactory in most cases.